Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Dyslipidemia

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 11 articles:
HTML format
Text format



Single Articles


    February 2016
  1. SEBBEN JC, Pinto Ribeiro DR, Lopes RD, de Winter R, et al
    The role of diabetes mellitus in the composition of coronary thrombi in patients presenting with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Am Heart J. 2016;172:26-33.
    PubMed     Text format     Abstract available


    December 2015
  2. DASARI TW, Saucedo JF, Krim S, Alkhouli M, et al
    Clinical characteristics and in hospital outcomes of heart transplant recipients with allograft vasculopathy undergoing percutaneous coronary intervention: Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2015;170:1086-91.
    PubMed     Text format     Abstract available


    October 2015
  3. WEIJMANS M, van der Graaf Y, de Borst GJ, Asselbergs FW, et al
    The relation between the presence of cardiovascular disease and vascular risk factors in offspring and the occurrence of new vascular events in their parents already at high vascular risk.
    Am Heart J. 2015;170:744-752.
    PubMed     Text format     Abstract available


    September 2015
  4. KO MJ, Kim YJ, Park CM, Lee SM, et al
    Applicability and potential clinical effects of 2013 cholesterol guidelines on major cardiovascular events.
    Am Heart J. 2015;170:598-605.
    PubMed     Text format     Abstract available


    August 2015
  5. HUNG RK, Al-Mallah MH, Qadi MA, Shaya GE, et al
    Cardiorespiratory fitness attenuates risk for major adverse cardiac events in hyperlipidemic men and women independent of statin therapy: The Henry Ford ExercIse Testing Project.
    Am Heart J. 2015;170:390-9.
    PubMed     Text format     Abstract available


    June 2015
  6. EREZ A, Kivity S, Berkovitch A, Milwidsky A, et al
    The association between cardiorespiratory fitness and cardiovascular risk may be modulated by known cardiovascular risk factors.
    Am Heart J. 2015;169:916-923.
    PubMed     Text format     Abstract available


  7. KEREIAKES DJ, Robinson JG, Cannon CP, Lorenzato C, et al
    Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
    Am Heart J. 2015;169:906-915.
    PubMed     Text format     Abstract available


    May 2015
  8. HOVINGH GK, Smits LP, Stefanutti C, Soran H, et al
    The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study.
    Am Heart J. 2015;169:736-742.
    PubMed     Text format     Abstract available


    March 2015
  9. WANG B, Choudhry NK, Gagne JJ, Landon J, et al
    Availability and utilization of cardiovascular fixed-dose combination drugs in the United States.
    Am Heart J. 2015;169:379-386.
    PubMed     Text format     Abstract available


    December 2014
  10. KNOWLES JW, O'Brien EC, Greendale K, Wilemon K, et al
    Reducing the burden of disease and death from familial hypercholesterolemia: a call to action.
    Am Heart J. 2014;168:807-11.
    PubMed     Text format     Abstract available


    November 2014
  11. SCHWARTZ GG, Bessac L, Berdan LG, Bhatt DL, et al
    Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial.
    Am Heart J. 2014;168:682-689.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: